CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Ziprasidone hydrochloride

Ziprasidone hydrochloride

Last Updated: January 10, 2008

Result type: Reports

Project Number: SR0124-000

Product Line: Reimbursement Review

Generic Name: Ziprasidone hydrochloride

Brand Name: Zeldox

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Schizophrenia and related psychotic disorders

Indications: Schizophrenia and related psychotic disorders

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 14, 2008

Recommendation Type: List with clinical criteria and/or conditions

Ziprasidone hydrochloride

Files